Products
Maprotiline was commercially available in the form of dragées and as a solution for injection (Ludiomil). It had been approved in many countries since 1972 and was withdrawn from the market in 2011 (solution for injection) and 2014 (dragées) for commercial reasons.
Structure and properties
Maprotiline (C20H23N, Mr = 277.4 g/mol) is in the form of maprotiline hydrochloride, a white crystalline powder that is sparingly soluble in water.
Effects
Maprotiline (ATC N06AA21) has antidepressant, antianxiety, antihistamine, and anticholinergic properties.
Indications
For the treatment of depressive episodes, recurrent depressive disorder, or major depression.
